0000950170-24-040358.txt : 20240402
0000950170-24-040358.hdr.sgml : 20240402
20240402171433
ACCESSION NUMBER: 0000950170-24-040358
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240402
DATE AS OF CHANGE: 20240402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lees-Rolfe Garth
CENTRAL INDEX KEY: 0002017374
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39676
FILM NUMBER: 24815535
MAIL ADDRESS:
STREET 1: 1 CRANBERRY HILL
STREET 2: SUITE 200
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc.
CENTRAL INDEX KEY: 0001750149
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263407249
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
BUSINESS PHONE: 678-392-3419
MAIL ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
4
1
ownership.xml
4
X0508
4
2024-04-01
0001750149
Inhibikase Therapeutics, Inc.
IKT
0002017374
Lees-Rolfe Garth
1 CRANBERRY HILL, SUITE 200
LEXINGTON
MA
02421
false
true
false
false
Chief Financial Officer
false
Stock Option (right to buy)
2.16
2024-04-01
4
A
false
90000
0.00
A
2031-04-01
Common Stock
90000
90000
D
One-third of the options will vest and become exercisable on April 1, 2025, one-third of the options will vest and become exercisable on April 1, 2026, and one-third of the options will vest and become exercisable on April 1, 2027, in each case subject to continued employment through each such vesting date.
/s/ Garth Lees-Rolfe
2024-04-02